GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Gemcitabine-Radiation for Advanced Pancreatic Cancer

$343,925
Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2007 · CA

Gemcitabine-Radiation for Advanced Pancreatic Cancer

$343,925
Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2009 · CA

Gemcitabine-Radiation for Advanced Pancreatic Cancer

$343,925
Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2010 · CA

Phosphorylation-dependent regulation of GLI transcription factors

$343,891
Scott Atwood · University Of California-Irvine · R01 · FY2019 · CA

Dissecting Hedgehog, TGF beta and BMP Signaling During Pancreatic Tumorigenesis

$343,867
Brian C Lewis · Univ Of Massachusetts Med Sch Worcester · R01 · FY2011 · CA

Role of the BMP SMADs in Oncogenesis

$343,739
Stephanie A Pangas · Baylor College Of Medicine · R01 · FY2014 · CA

Heparanase in Tumor Progression, Metastasis and Chemoresistance

$343,602
Ralph D Sanderson · University Of Alabama At Birmingham · R01 · FY2019 · CA

Regulation of Exocrine Pancreatic Progenitors by Ptf1a-p48

$343,413
Steven D Leach · Johns Hopkins University · R01 · FY2009 · DK

Obesity and Pancreatic Cancer: The Role of IGF-1

$343,390
Susan M Fischer · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA

Targeting immune stroma interactions in pancreatic cancer

$343,355
Gregory B. Lesinski · Emory University · R01 · FY2019 · CA

Nanotechnology enabled targeting of p53 deficiency in human cancer

$343,342
Xiaoming He · Univ Of Maryland, College Park · R01 · FY2019 · CA

Targeting transient receptor potential channels to suppress proviral mitochondrial fission and mitophagy in order to mitigate CVB pancreatitis

$343,200
Jon Sin · University Of Texas Dallas · R01 · FY2025 · DK

NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY

$343,125
Jeremiah J Morrissey · Washington University · R01 · FY2017 · CA

MECHANISMS OF CHIEF CELL DEDIFFERENTIATION

$343,125
Jason C Mills · Washington University · R01 · FY2017 · DK

NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY

$343,125
Jeremiah J Morrissey · Washington University · R01 · FY2018 · CA

NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY

$343,125
Jeremiah J Morrissey · Washington University · R01 · FY2016 · CA

MECHANISMS OF CHIEF CELL DEDIFFERENTIATION

$343,125
Jason C Mills · Washington University · R01 · FY2015 · DK

MECHANISMS OF CHIEF CELL DEDIFFERENTIATION

$343,125
Jason C Mills · Washington University · R01 · FY2016 · DK

Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc

$343,092
Ram I Mahato · University Of Nebraska Medical Center · R01 · FY2014 · EB

Genomic Clinical Variant Expert Curation Panel for Monogenic Diabetes: A Gateway to Precision Medicine in Diabetes Mellitus

$343,083
Toni I. Pollin · University Of Maryland Baltimore · U24 · FY2024 · HD

Genomic Clinical Variant Expert Curation Panel for Monogenic Diabetes: A Gateway to Precision Medicine in Diabetes Mellitus

$343,083
Toni I. Pollin · University Of Maryland Baltimore · U24 · FY2025 · HD

Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs

$343,015
Kevin J Yarema · Johns Hopkins University · R01 · FY2022 · CA

Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells

$342,972
Chrystal Mary Paulos · Medical University Of South Carolina · R01 · FY2018 · CA

ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer

$342,938
Min Li · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2018 · CA

ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer

$342,938
Min Li · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2017 · CA